Enveric Biosciences 과거 수익 실적

과거 기준 확인 0/6

Enveric Biosciences의 수입은 연평균 -19.4%의 비율로 감소해 온 반면, Pharmaceuticals 산업의 수입은 연간 증가했습니다(12.9%).

주요 정보

-19.4%

수익 성장률

21.2%

EPS 성장률

Pharmaceuticals 산업 성장	7.3%
매출 성장률	n/a
자기자본 수익률	-249.5%
순이익	n/a
최근 수익 업데이트	30 Sep 2024

최근 과거 실적 업데이트

업데이트 없음

Recent updates

수익 및 비용 분석

Enveric Biosciences 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

DB:SLZA 수익, 비용 및 수입 (USD Millions )
날짜	수익	G+A 비용	R&D 비용
30 Sep 24	-10	5	3
30 Jun 24	-11	6	4
31 Mar 24	-15	8	6
31 Dec 23	-17	9	7
30 Sep 23	-23	11	7
30 Jun 23	-23	13	8
31 Mar 23	-19	12	8
31 Dec 22	-19	12	8
30 Sep 22	-52	18	9
30 Jun 22	-52	16	8
31 Mar 22	-50	16	7
31 Dec 21	-49	20	5
30 Sep 21	-11	14	2
30 Jun 21	-9	13	1
31 Mar 21	-9	11	0
31 Dec 20	-7	5	0
30 Sep 20	-3	2	0
30 Jun 20	-3	2	0
31 Mar 20	-3	3	0
31 Dec 19	-2	2	0
30 Sep 19	-3	3	0
31 Dec 18	-2	2	0

양질의 수익: SLZA 은(는) 현재 수익성이 없습니다.

이익 마진 증가: SLZA 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: SLZA 은(는) 수익성이 없으며 지난 5년 동안 연간 19.4% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 SLZA 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: SLZA 은(는) 수익성이 없어 지난 해 수익 성장을 Pharmaceuticals 업계( 25.4% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: SLZA 현재 수익성이 없기 때문에 마이너스 자본 수익률( -249.45% )을 갖습니다.

Enveric Biosciences 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Recent updates

Enveric Biosciences Announces Completion of Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-Like Behavior

The Listing Qualifications Department of the Nasdaq Stock Market Issues A Determination to Enveric Biosciences

The Listing Qualifications Department of the Nasdaq Stock Market Issues A Determination to Enveric Biosciences

New major risk - Financial position

Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003

New major risk - Financial position

Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to Be Dosed Orally

New major risk - Share price stability

Enveric Biosciences Regains Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market Pursuant to Nasdaq Listing Rule 5550(b)(1)

Enveric Biosciences Receives Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Pursuant to Nasdaq Marketplace Rule 5550(a)(2)

New major risk - Financial position

High number of new and inexperienced directors

Enveric Biosciences, Inc., Annual General Meeting, May 28, 2024

New major risk - Shareholder dilution

Enveric Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $0.322453 million.

Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders

Enveric Biosciences Receives Notice from the Nasdaq Stock Market

New major risk - Share price stability

Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series

Enveric Biosciences Selects Development Candidates from Evm301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived Compounds

Enveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal Chemistry

Enveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal Chemistry

Enveric Biosciences Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Enveric Biosciences Initiates GLP Toxicology & Safety Pharmacology Studies for Lead Candidate EB-373

Enveric Biosciences, Inc., Annual General Meeting, Nov 02, 2023

Enveric Biosciences Completes Manufacturing of EB-373 to Supply Drug Material for Completion of Preclinical Program

High number of new and inexperienced directors

Enveric Biosciences, Inc. Reports Positive Results from Preclinical Studies Supporting Metabolic Profile of Lead Candidate EB-373

Enveric Biosciences Reports Positive Results from Animal Studies Demonstrating Oral Bioavailability and Well Tolerated Side Effect Profile for EB-373

Enveric Biosciences, Inc. Announces Development of Phase 1-Ready Formulation for EB-373 and Initiation of Scaled Up Manufacturing

Enveric Biosciences, Inc. Announces Manuscript Detailing the Development of Novel Psilocin Prodrugs for the Treatment of Anxiety and Other Mental Health Disorders

Enveric Biosciences, Inc. Receives Notice of Allowance from Uspto for Novel Prodrug of Psilocin

High number of new and inexperienced directors

High number of new and inexperienced directors

Enveric Biosciences, Inc. Advances Lead Candidate for the Treatment of Anxiety Disorders to IND-Enabling Studies

Enveric Biosciences, Inc., Annual General Meeting, Oct 28, 2022

Enveric Biosciences, Inc. Appoints Robert Dickey IV as Chief Financial Officer

Enveric Biosciences, Inc. Regains Compliance with Listing Rule 5550(a)(2) Letter from the Listing Qualifications Department of Nasdaq

Enveric Biosciences, Inc. Appoints New Independent Directors

Enveric Biosciences, Inc. announced that it expects to receive $5 million in funding

Enveric Biosciences Announces Formation of Scientific Advisory Board to Drive Further Growth of Next-Generation Mental Health Medicines

Enveric Biosciences, Inc. Announces Appointment of Frank Pasqualone to the Board of Directors

Enveric Biosciences Announces Management Appointments

High number of new and inexperienced directors

Enveric Biosciences, Inc. Expands Portfolio of Drug Development Candidates and Files New Provisional Patent Application

Enveric Biosciences Files Portfolio of Patent Applications for Tryptamine-Based Molecules

Enveric Biosciences, Inc. announces development of EV104a and EV104b

Enveric Biosciences, Inc. (NasdaqCM:ENVB) entered into a definitive agreement to acquire MagicMed Industries Inc.

Enveric Biosciences, Inc. announced delayed annual 10-K filing

Enveric Biosciences, Inc. Appoints Dr. Douglas D. Lind to Company's Board of Directors

Enveric Biosciences, Inc. (NasdaqCM:ENVB) completed the acquisition of Exclusive and perpetual license for Diverse Biotech novel molecules from Diverse Biotech, Inc.

수익 및 비용 분석

수익 및 매출 내역

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

자기자본 수익률

자산 수익률

고용 자본 수익률

과거 성과가 우수한 기업 찾기